Ozempic for Weight Loss After 65: What the Research Shows

If you are over 65 and have been told that GLP-1 medications are not for you, or if you have simply wondered whether they actually work at your age, new research has something important to say. Semaglutide, the active ingredient in Ozempic, appears to deliver meaningful weight loss in older adults, not just the younger populations that dominate most clinical headlines.

This matters. Obesity in older adults is associated with a distinct set of risks: reduced mobility, joint deterioration, cardiovascular strain, and a higher likelihood of metabolic complications. For years, many physicians were hesitant to recommend aggressive weight loss interventions for patients over 65, citing concerns about muscle loss, frailty, and tolerability. This new research challenges that hesitation with actual data.

What the Study Found

The study examined how well semaglutide performed specifically in adults aged 65 and older, filling a real gap in the existing evidence base. Most landmark GLP-1 trials, including the SUSTAIN and STEP series, enrolled predominantly younger and middle-aged adults. Older patients were either excluded or represented in small numbers that made it difficult to draw meaningful conclusions for this age group.

The findings indicate that adults over 65 achieved substantial weight reduction on semaglutide. While the specific figures from this study should be discussed with your own provider in context, the direction of the evidence is clear: age alone does not appear to blunt the drug's effectiveness on body weight.

This aligns with what endocrinologists and obesity medicine specialists have observed clinically. The biological mechanisms behind GLP-1 receptor agonists, including appetite suppression and slowed gastric emptying, do not simply stop working once a person crosses an age threshold.

Why This Age Group Has Been Underrepresented

Clinical trials have historically skewed younger. Researchers often exclude older adults to reduce confounding variables, including the presence of multiple chronic conditions (called comorbidities) and the use of multiple medications (polypharmacy). While this makes trial data cleaner, it also leaves physicians without strong evidence to guide treatment in a population that arguably needs effective interventions the most.

Adults over 65 carry a disproportionate burden of obesity-related disease. According to data from the CDC, roughly 42 percent of U.S. adults are affected by obesity, and rates remain high into older age groups. Yet the treatment conversation for older patients has lagged behind.

This new study represents a step toward closing that evidence gap. It gives clinicians something concrete to reference when evaluating whether semaglutide is appropriate for their older patients, and it gives patients themselves a more informed starting point for those conversations.

Key Safety Considerations for Older Adults

Effectiveness is one part of the picture. Tolerability and safety are equally important, especially for patients managing multiple health conditions or taking several medications at once.

Muscle Mass and Functional Strength

One of the most discussed concerns with GLP-1 medications in older adults is the potential for muscle loss alongside fat loss. This is not unique to older patients, but the consequences are more significant. Sarcopenia, the age-related loss of muscle mass and strength, is already a concern in this population. Adding weight loss without preserving lean muscle can increase fall risk and reduce functional independence.

The practical response is not to avoid the medication. It is to pair it with intentional resistance training and adequate protein intake. Most guidelines recommend at least 1.2 grams of protein per kilogram of body weight per day for older adults on caloric restriction. A registered dietitian familiar with GLP-1 therapy can help build a plan that protects muscle while supporting fat loss.

Drug Interactions and Polypharmacy

Adults over 65 are more likely to be taking medications for blood pressure, cholesterol, blood sugar, thyroid function, or other conditions. Some of these, particularly insulin and sulfonylureas for diabetes, can interact with semaglutide in ways that affect blood sugar levels. Your prescribing physician needs a complete medication list before starting you on any GLP-1 drug.

Slower gastric emptying caused by semaglutide can also affect how quickly other oral medications are absorbed. This is not always clinically significant, but it is worth discussing with your doctor and pharmacist.

Gastrointestinal Side Effects

Nausea, constipation, and reduced appetite are the most commonly reported side effects of semaglutide. In older adults, reduced appetite on top of an already suppressed baseline intake can sometimes lead to inadequate caloric consumption. Dehydration from GI symptoms can also be more serious in older patients. Starting at the lowest dose and titrating slowly is especially important in this group.

How Ozempic Compares to Other GLP-1 Options for Older Adults

Wegovy, which contains the same active ingredient semaglutide at a higher dose, carries an FDA approval specifically for chronic weight management.

Mounjaro, which contains tirzepatide and targets two gut hormone receptors instead of one, has shown even larger average weight loss in clinical trials. However, data specifically in adults over 65 is still emerging for tirzepatide, while the semaglutide evidence base is now growing more robust.

Prices above are approximate list prices and vary by pharmacy and plan. Always check whether your Medicare or private insurance plan covers any of these medications.

Does Medicare Cover Ozempic or Wegovy for Older Adults?

This is one of the most practical questions for patients in this age group, and the answer is nuanced. Medicare Part D covers Ozempic when it is prescribed for type 2 diabetes. However, as of this writing, Medicare does not cover Wegovy or other GLP-1 drugs when prescribed solely for weight loss, though coverage policy continues to evolve.

This creates a situation where older adults with both diabetes and obesity may have an easier path to coverage than those who have obesity alone. If you have a diabetes diagnosis, your physician may prescribe Ozempic with that indication in mind, which can open the door to coverage.

For those without a diabetes diagnosis seeking GLP-1 therapy for weight loss, out-of-pocket costs can be significant. Checking available GLP-1 coupons and manufacturer savings programs is a worthwhile step, though eligibility requirements vary and Medicare beneficiaries are often excluded from manufacturer coupons.

Questions to Ask Your Doctor Before Starting

If you are over 65 and considering semaglutide, preparation matters. Here are specific questions that will help you have a more productive conversation with your physician.

• Given my age, current health conditions, and the medications I am taking, do you consider me a safe candidate for semaglutide, and are there any specific risks in my profile that would make you hesitant or require additional monitoring?
• What is your recommended protein intake target for me to protect my lean muscle mass during GLP-1-driven weight loss, and should I be working with a dietitian to ensure I am hitting that target given my reduced appetite?
• Are any of my current medications, particularly any diabetes drugs, blood thinners, or thyroid medications, likely to interact with semaglutide or be affected by the slowed gastric emptying it produces?
• What titration schedule would you recommend for someone my age, and would you start more conservatively than the standard protocol to reduce the risk of dehydration or excessive appetite suppression?
• Does my Medicare Part D plan cover Ozempic for my specific diagnosis, and if not, what documentation or prior authorization steps can we take to pursue coverage or explore manufacturer assistance programs?
• How will we monitor my muscle mass and functional strength during treatment, and at what point would you want to see me for follow-up after starting, particularly given the higher risk of sarcopenia in my age group?
• If I experience gastrointestinal side effects severe enough to significantly reduce my food and fluid intake, at what threshold should I contact your office rather than waiting for my next scheduled appointment?

Bringing a written list of your current medications to this appointment is practical, not optional. It allows your prescriber to review the full picture before writing a prescription.

Choosing the Right Provider

Not every telehealth platform or physician is equally equipped to manage GLP-1 therapy in older adults. Some platforms operate efficiently for healthy younger patients but lack the infrastructure to handle complex medication reviews, insurance authorization for Medicare plans, or close monitoring of patients with comorbid conditions.

When evaluating GLP-1 providers, look for those that offer direct access to a physician or advanced practice provider (not just a chatbot intake), ongoing follow-up visits rather than one-and-done prescriptions, and familiarity with Medicare and insurance navigation for older patients.

In-person obesity medicine specialists or endocrinologists may be the right choice if you are managing several chronic conditions alongside weight. They can coordinate with your primary care physician and other specialists to ensure that semaglutide is introduced safely and monitored appropriately.